Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Covalon Technologies Ltd CVALF


Primary Symbol: V.COV

Covalon Technologies Ltd. is a Canada-based patient-driven medical device company that provides healthcare solutions for advanced wound care, infection control, and medical device coatings. The Company's solutions are designed for patients and made for care providers. The Company leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon's name, and by developing and commercializing medical products for other medical companies under development and license contracts. The Company has three proprietary platform technologies that have the potential to be developed into a number of medical devices and products: Collagen matrix, Antimicrobial silicone adhesive and Medical coatings. Its product type includes advanced wound care, antimicrobial dressings, collagen dressings, IV dressings, and perioperative dressings. Its brands include ColActive PLUS, CovaClear, CovaView, CovaWound, IV Clear, SurgiClear, and VALGuard.


TSXV:COV - Post by User

Comment by ARIMA11on Aug 16, 2023 11:13am
55 Views
Post# 35590964

RE:RE:Interesting

RE:RE:Interesting
mcappro wrote: Where are they using $2-$3M per quarter?  The recent annual performance shows just over $1.1M in Adjusted EBITDA loss (cash burn) for the 9 months for fiscal 2023.  The company has a strong balance sheet and no debt, increasing revenues and good gross margins.  I don't see a lot of downside risk here, albeit the microcap market is unpredictable and does not reflect the value of the company at these levels.  The institution of a share buyback program will continue to benefit the long term shareholders.  I did not get the impression that a share buyback is not going to be put into place from the CEO's comments, perhaps they needed to be outside of the earnings blackout period to do so - which they are now, I believe.  


Look at the cash balance on a quarterly basis.... It's not going up... :)
<< Previous
Bullboard Posts
Next >>